NASDAQ:JBIO Jade Biosciences Q2 2026 Earnings Results & Report $13.44 +0.02 (+0.15%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$13.50 +0.06 (+0.45%) As of 08:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jade Biosciences missed analyst earnings expectations in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.76 versus the -$0.66 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Jade Biosciences EPS ResultsActual EPS-$0.76Consensus EPS -$0.66Beat/MissMissed by -$0.10One Year Ago EPSN/AEPS Beat Rate2 of last 5 quartersJade Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Jade Biosciences Q2 2026 Earnings FAQ Did Jade Biosciences beat earnings estimates for Q2 2026? Jade Biosciences (NASDAQ:JBIO) reported earnings of -$0.76 per share for Q2 2026, missing the consensus estimate of -$0.66. The report was announced on Monday, August 10, 2026. Jade Biosciences Earnings HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA)October 2, 2026 | theglobeandmail.comAnalysts Are Bullish on Top Healthcare Stocks: Inogen (INGN), Jade Biosciences (JBIO)October 2, 2026 | theglobeandmail.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 15 at 1:00 AM | Profits Run (Ad)Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - SlideshowSeptember 30, 2026 | seekingalpha.comJade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis TranscriptSeptember 30, 2026 | seekingalpha.comJade Bioscience Reports Preclinical Data For JADE301September 30, 2026 | rttnews.comSee More Jade Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email. Email Address About Jade BiosciencesJade Biosciences (NASDAQ:JBIO) is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research and development efforts are directed toward antibody-based medicines designed to address significant unmet needs in immune-mediated conditions. Jade’s pipeline includes investigational therapeutic programs intended to modulate biological pathways involved in inflammation and immune-system activity. As a development-stage company, its products remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or reach the commercial market. The company is headquartered in the United States and is developing its portfolio for potential use in global markets. Publicly available information about Jade Biosciences’ commercial operations and marketed products remains limited because the company is focused primarily on advancing its clinical pipeline.View Jade Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
